| Code | CSB-RA004936MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Abiprubart, targeting CD40, a costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is predominantly expressed on antigen-presenting cells, including B lymphocytes, dendritic cells, and macrophages, where it plays a critical role in adaptive immune responses. Upon binding with its ligand CD40L, CD40 initiates signaling cascades that regulate B cell activation, immunoglobulin class switching, and germinal center formation. Dysregulated CD40-CD40L interactions are implicated in various autoimmune disorders, inflammatory conditions, and hematological malignancies, making this pathway an important therapeutic target.
Abiprubart is a human IgG1 monoclonal antibody designed to modulate CD40 signaling and has been investigated for its potential in treating autoimmune diseases and transplant rejection. This biosimilar antibody provides researchers with a valuable tool for investigating CD40-mediated immune mechanisms, studying costimulatory pathway blockade, and exploring therapeutic interventions in immune-related disorders. It serves as an essential reagent for preclinical studies examining immune regulation and B cell biology.
There are currently no reviews for this product.